Semaglutide: what you need to know about online supply and effective use
Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the… read more.
Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the… read more.
Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist… read more.
Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has… read more.
Too Few Primary Care Doctors Address Obesity With Their Patients, Highlighting Need for Weight Loss Tool After finding that few to no clinicians provided weight management care, researchers… read more.
A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant… read more.
Adults at high cardiovascular risk and living with overweight or obesity [1] experience a higher number of cardiovascular events (such as heart attack and stroke), are at greater… read more.
Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.
Professor Alex Miras, consultant endocrinologist at the University of Ulster, takes the view that obesity is a disease. He explains why this is and how the SELECT trial… read more.
GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older… read more.
Semaglutide works well on its own as obesity treatment but it works even better with the support and guidance of a multi-disciplinary weight-management team, according to Alex Miras,… read more.
In March 2023 the National Institute for Health and Care Excellence (NICE) published Technology Appraisal Guidance for semaglutide for obesity. Professor Alex Miras explains the guidance and its… read more.
Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.